Vertex Grabs $105M in Amended Telaprevir Deal with Mitsubishi | Xconomy30 Jul
More creative biotech funding, this time from Boston-based Vertex to develop and market their Hepatitis C protease inhibitor Telaprevir. Mitsubishi Tanabe Pharma is putting $105M of its money where its mouth is for the rights to market this potential blockbuster in Asia.